ライフサイエンスコーパス: squamous cell carcinoma

1 of Tgfbr2-deficient invasive transition zone squamous cell carcinoma.

2 ctinic keratosis is a precursor to cutaneous squamous cell carcinoma.

3 ochemistry in 96 patients with head and neck squamous cell carcinoma.

4 poor prognosis in melanoma and head and neck squamous cell carcinoma.

5 r smokers and in participants diagnosed with squamous cell carcinoma.

6 rom the HF junctional zone and predispose to squamous cell carcinoma.

7 vival of five cancers, such as head and neck squamous cell carcinoma.

8 keratinocytes, the cell-type susceptible to squamous cell carcinoma.

9 prostate cancer, urothelial cancer, and skin squamous cell carcinoma.

10 associated with skin keratosis and cutaneous squamous cell carcinoma.

11 ll proportion of the disease can progress to squamous cell carcinoma.

12 was not observed in patients with esophageal squamous cell carcinoma.

13 ity, photosensitivity, and increased risk of squamous cell carcinoma.

14 h T1/T2 clinically node-negative oral cavity squamous cell carcinoma.

15 of miR-203-induced transcriptomic changes in squamous cell carcinoma.

16 harbor high-grade dysplasia or even invasive squamous cell carcinoma.

17 l features with their malignant counterpart, squamous cell carcinoma.

18 marker and therapeutic target for cutaneous squamous cell carcinoma.

19 candidiasis, hypothyroidism, and esophageal squamous cell carcinoma.

20 up-regulated in human actinic keratosis and squamous cell carcinoma.

21 t to CHCT/MRI in patients with head and neck squamous cell carcinoma.

22 ed in national registries, such as basal and squamous cell carcinomas.

23 metimes with keratin pearls, consistent with squamous cell carcinomas.

24 ting toxicity in patients with head and neck squamous cell carcinomas.

25 ntigen for cancer diagnosis specifically for squamous cell carcinomas.

26 e (PI3Kalpha), are frequent in head and neck squamous cell carcinomas.

27 All 11 patients developed a squamous cell carcinoma (14 malignancies), and 1 patient

28 ophageal cancer (84.7% adenocarcinoma, 15.2% squamous cell carcinoma), 335 (9.3%) were treated with A

29 ted, 287 (62.8%) were BCCs, 106 (23.2%) were squamous cell carcinoma, 39 (8.5%) were lichen planus-li

30 eal adenocarcinomas, 323 cases of esophageal squamous cell carcinoma, 698 cases of gastric cardia ade

31 In other types of squamous epithelia and squamous cell carcinomas, a similar control mechanism is

32 Squamous cell carcinoma affecting the periocular region

33 ma, esophageal adenocarcinoma, or esophageal squamous cell carcinoma.Among older American adults, bot

34 zard ratios across subgroups, including both squamous cell carcinoma and adenocarcinoma, both cN0 and

35 because it contains two main types, namely, squamous cell carcinoma and adenocarcinoma.

36 sive phenotypes in lung adenocarcinoma, lung squamous cell carcinoma and breast carcinoma cancer cell

37 The effects were stronger for squamous cell carcinoma and ever smokers for the "fruits

38 epidermal development, psoriasis, cutaneous squamous cell carcinoma and re-epithelisation are highli

39 The most common aetiology was squamous cell carcinoma and the majority of cases (30%)

40 as a predictive marker for HDACi response in squamous cell carcinomas and lymphomas, and unveiled let

41 increase was seen in Bowen disease, invasive squamous cell carcinoma, and a superficial type of basal

42 monstrates PD-L1 detection in NSCLC, breast, squamous cell carcinoma, and melanoma.

43 in lung adenocarcinoma as compared with lung squamous cell carcinoma, and that neutrophils are the mo

44 fty-six percent had adenocarcinomas, 34% had squamous cell carcinomas, and 10% had another histology.

45 Squamous cell carcinoma antigen (SCCA) is a good specifi

46 d its capability in quantitative analysis of squamous cell carcinoma antigen in human serum with reco

47 ak current variation to the concentration of squamous cell carcinoma antigen in the range of 0.001-0.

48 borrheic keratosis) or mutant p53 (cutaneous squamous cell carcinoma) appears to dictate whether a le

49 volved in the progression of transition zone squamous cell carcinoma are poorly understood, hence rep

50 Basal and squamous cell carcinoma are the most common types of can

51 Oral squamous cell carcinomas are a major cause of morbidity

52 The aim of this article is to describe oral squamous cell carcinoma as it appears in different imagi

53 ith histologically verified primary head and squamous cell carcinoma at Odense University Hospital fr

54 in the pharyngeal mucosal space (n=16) with squamous cell carcinoma being the most common pathology.

55 t nodal dissection for mucosal head and neck squamous cell carcinoma between 2004 and 2013.

56 tients treated by chemoradiotherapy for anal squamous cell carcinoma between October 2007 and October

57 ession in human breast, lung, and esophageal squamous cell carcinoma cancer xenografts.

58 analyses of patients with EGFR FISH-positive squamous-cell carcinoma cancers are encouraging and supp

59 In addition to esophageal squamous cell carcinoma, cancers of the small bowel, pan

60 re being treated for basal cell carcinoma or squamous cell carcinoma (cases) and 100 individuals who

61 SCC-25 cells, a human squamous cell carcinoma cell line, and primary keratinoc

62 We show here that in both squamous cell carcinoma cells and melanoma tumor cells,

63 against naturally HPV-infected head and neck squamous cell carcinoma cells using IFN-gamma ELISPOT an

64 Here, using mouse squamous cell carcinoma cells, we report a completely ne

65 GFR with GFP by genome-editing of human oral squamous cell carcinoma cells, which were used to examin

66 nd, like JunB, it was downregulated in human squamous cell carcinoma cells.

67 Perineural invasion (PNI) in cutaneous squamous cell carcinoma (CSCC) has been associated with

68 nsformation of normal epidermis to cutaneous squamous cell carcinoma (cSCC) is causally linked to alt

69 Cutaneous squamous cell carcinoma (cSCC) is one of the most common

70 Keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is the most common metast

71 Cutaneous squamous cell carcinoma (cSCC) is the second most common

72 ified genetic loci associated with cutaneous squamous cell carcinoma (cSCC) risk, but single-nucleoti

73 have a 100-fold increased risk of cutaneous squamous cell carcinoma (cSCC).

74 s with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC).

75 was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy i

76 dvantage on normal and neoplastic (cutaneous squamous cell carcinoma, cSCC) human epidermal cells.

77 Cutaneous squamous cell carcinoma (cuSCC) comprises 15-20% of all

78 ted with CD44, HAS3, and ABCC1 expression in squamous cell carcinoma datasets and p63-HA pathway is a

79 tudy, we determined that human head and neck squamous cell carcinoma-derived HSC-3 cells contain a su

80 ons on the cellular and molecular origins of squamous cell carcinoma due to oncogenic mutations in Ra

81 -wide association study (GWAS) on esophageal squamous cell carcinoma (ESCC) in Han Chinese, we conduc

82 Esophageal squamous cell carcinoma (ESCC) is among the most common

83 Data of 1095 esophageal squamous cell carcinoma (ESCC) patients, including 679 i

84 issues removed from patients with esophageal squamous cell carcinoma (ESCC) with poor prognosis, and

85 ophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), although evidence is lim

86 h enhanced malignant potential in esophageal squamous cell carcinoma (ESCC), among the deadliest of a

87 have efficacy in EGFR-amplified oesophageal squamous cell carcinoma (ESCC), but may become quickly i

88 e to chronic fungal infection and esophageal squamous cell carcinoma (ESCC).

89 chemoresistance in patients with esophageal squamous cell carcinoma (ESCC).

90 half of the world's 500,000 new oesophageal squamous-cell carcinoma (ESCC) cases each year occur in

91 as (EACs) and EGFR overexpressing esophageal squamous cell carcinomas (ESCCs).

92 Critically, in head and neck squamous cell carcinoma, Fxr1 overexpression correlates

93 But the biological effect of SDT on oral squamous cell carcinoma has not been studied.

94 tions in which, although common in cutaneous squamous cell carcinoma, have not been identified in SKs

95 lanoma skin cancers, in particular cutaneous squamous cell carcinoma, have the highest standardized i

96 which were frequently dysregulated in human squamous cell carcinomas, highlighting their potential a

97 define an intrinsic subtype of head and neck squamous cell carcinoma (HNSC) that features pronounced

98 Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 90%

99 cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that pred

100 potential relationship between head and neck squamous cell carcinoma (HNSCC) and microbial dysbiosis,

101 is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) and other cancers.

102 to examine whether staging of head and neck squamous cell carcinoma (HNSCC) by upfront (18)F-FDG PET

103 panel of 49 established human head and neck squamous cell carcinoma (HNSCC) cell lines and report th

104 l Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC) cell lines and was due t

105 phenotypes in patient-derived head and neck squamous cell carcinoma (HNSCC) cells in vitro and in vi

106 papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to

107 Head and neck squamous cell carcinoma (HNSCC) includes epithelial canc

108 Head and neck squamous cell carcinoma (HNSCC) is a leading cause of ca

109 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common

110 Head and neck squamous cell carcinoma (HNSCC) patients have a poor pro

111 ely 6,000 single cells from 18 head and neck squamous cell carcinoma (HNSCC) patients, including five

112 apillomavirus-related (HPV(+)) head and neck squamous cell carcinoma (HNSCC) samples.

113 e cell growth of p53-deficient head and neck squamous cell carcinoma (HNSCC) UM-SCC-1 cells both in i

114 ne and metabolic phenotypes in head and neck squamous cell carcinoma (HNSCC) were assessed and change

115 nt-resistant head and neck tumors, including squamous cell carcinoma (HNSCC), adenoid cystic carcinom

116 nt-resistant head and neck tumors, including squamous cell carcinoma (HNSCC), adenoid cystic carcinom

117 clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking ant

118 ectively inhibit the growth of head and neck squamous cell carcinoma (HNSCC).

119 the survival of patients with head and neck squamous cell carcinoma (HNSCC).

120 h the p53 family member p63 in head and neck squamous cell carcinoma (HNSCC).

121 various cancers, including the head and neck squamous cell carcinoma (HNSCC).

122 us (HPV) detection and risk of head and neck squamous cell carcinoma (HNSCC).

123 sion is a hallmark of advanced head and neck squamous cell carcinoma (HNSCC).

124 defective molecular switch in head and neck squamous cell carcinoma (HNSCC).

125 Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance t

126 nome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the most frequen

127 Patients with HPV-positive head neck squamous cell carcinomas (HNSCC) usually have a better p

128 ed by stromal fibroblasts from head and neck squamous cell carcinomas (HNSCC).

129 papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCCs) are deadly and common

130 Head and neck squamous cell carcinomas (HNSCCs) are refractory to ther

131 owever, more recent studies of head and neck squamous cell carcinomas (HNSCCs) suggest that integrati

132 he absence of p53, Nanog induces spontaneous squamous cell carcinoma, identifying a novel role of Nan

133 n exposure, IL-6 promoter variants, and lung squamous cell carcinoma in former uranium miners.

134 lopment of UV irradiation-mediated cutaneous squamous cell carcinoma in mice.

135 ential therapeutic targets for prevention of squamous cell carcinoma in patients with Kindler syndrom

136 Squamous cell carcinoma in the head and neck (HNSCC) is

137 two (4%), nausea in two (4%), and cutaneous squamous cell carcinoma in two (4%).

138 All squamous cell carcinomas in blacks were diagnosed in the

139 Oesophageal squamous cell carcinoma is a deadly disease where system

140 Esophageal squamous cell carcinoma is a major histological type of

141 y genomic studies in other cancer types.Oral squamous cell carcinoma is a prevalent malignancy in Tai

142 Oral squamous cell carcinoma is a prominent cancer worldwide,

143 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes.

144 gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cancer cells were studi

145 eck in locoregionally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after concurrent chemo

146 iling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental mo

147 specific copy number gain (CNG) in both lung squamous cell carcinoma (LSCC) and ovarian serous carcin

148 TF), a measure of tumor invasiveness of lung squamous cell carcinoma (LSCC).

149 ibe a similar hypomethylated subtype of lung squamous cell carcinoma (LUSC) that is enriched for both

150 between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), two main lung cancer sub

151 In human lung adenocarcinomas and squamous cell carcinomas, membranous expression of PD-L1

152 a, classified as adenocarcinoma (n = 4,036), squamous cell carcinoma (n = 1,998), small cell carcinom

153 patients with nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC).

154 patients with nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC).

155 randomized trials on secondary prevention of squamous cell carcinoma observed a reduction in cumulati

156 Squamous cell carcinomas occurring at transition zones a

157 Adequate resection of oral cavity squamous cell carcinoma (OCSCC) means complete tumor rem

158 tures unique to human oral and oropharyngeal squamous cell carcinomas (OCSCC/OPSCC).

159 have recurrent copy-number variants in three squamous-cell carcinomas (oesophageal, head and neck and

160 ffect radiotherapy response and prognosis of squamous cell carcinoma of oropharynx (SCCOP).

161 Squamous cell carcinoma of the anal canal (SCCA) is a ra

162 Purpose Squamous cell carcinoma of the anal canal (SCCAC) is cha

163 Purpose Squamous cell carcinoma of the anal canal (SCCAC) is cha

164 In patients with squamous cell carcinoma of the anus (SCCA), lymph node p

165 se after chemoradiotherapy for patients with squamous cell carcinoma of the anus is 26 weeks from sta

166 the quality of outcome reporting in RCTs of squamous cell carcinoma of the anus is inconsistent.

167 h newly diagnosed, histologically confirmed, squamous cell carcinoma of the anus without metastatic d

168 ) of radical chemoradiation for treatment of squamous cell carcinoma of the anus.

169 hemoradiation for treatment of patients with squamous cell carcinoma of the anus.

170 Pain is often one of the first signs of squamous cell carcinoma of the head and neck (HNSCC).

171 chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

172 ucleus enhanced its interaction with PCNA in squamous cell carcinoma of the head and neck (SCCHN) cel

173 logically confirmed recurrent and metastatic squamous cell carcinoma of the head and neck after disea

174 Six patients with squamous cell carcinoma of the head and neck and 10 HT29

175 ositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes

176 platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few tr

177 Patients with recurrent or metastatic squamous cell carcinoma of the head and neck have few tr

178 ial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progres

179 nfirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck, and had an

180 titumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting

181 fe for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data

182 platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck.

183 platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck.

184 ebo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

185 d in 2004 to 2012 with AJCC stage III to IVB squamous cell carcinoma of the oral cavity, oropharynx,

186 had to include patients with non-metastatic squamous cell carcinoma of the oral cavity, oropharynx,

187 The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) showed

188 nt CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.

189 Purpose In squamous cell carcinomas of the head and neck (HNSCC), t

190 Squamous cell carcinomas of the head and neck (SCCHN) af

191 Basal cell and squamous cell carcinomas of the skin are the commonest c

192 dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have ad

193 wly diagnosed, biopsy-proven stage III or IV squamous-cell carcinoma of the oropharynx, positive for

194 n papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been reported predom

195 The incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increased more than

196 papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown resistance to

197 A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred t

198 papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is disproportionately hi

199 Purpose Treatment of oropharyngeal squamous cell carcinoma (OPSCC) is evolving toward risk-

200 apillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is treatment-responsive.

201 and a separate dataset of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) samples to identify diff

202 deline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to b

203 ), the increasing incidence of oropharyngeal squamous cell carcinomas (OPSCCs) is attributable to hum

204 es an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particularly in white

205 es an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particularly in white

206 .5%), 37 basal cell carcinomas (1.9%), and 1 squamous cell carcinoma or Bowen disease (0.1%).

207 d "cutaneous squamous cell carcinoma or skin squamous cell carcinoma or cSCC or nonmelanoma skin neop

208 used: "human papillomavirus" and "cutaneous squamous cell carcinoma or skin squamous cell carcinoma

209 g first-line treatment for patients with non-squamous cell carcinoma or squamous cell carcinoma (with

210 Human oral squamous cell carcinoma (OSCC) constitutes an inflammato

211 Most cases of oral squamous cell carcinoma (OSCC) develop from visible oral

212 FA patients develop oral squamous cell carcinoma (OSCC) earlier and more frequent

213 miR-211 expression in human oral squamous cell carcinoma (OSCC) has been implicated in po

214 Oral squamous cell carcinoma (OSCC) is the most common cancer

215 ogene, ROS1, as an important driver for oral squamous cell carcinoma (OSCC) metastasis.

216 Oral squamous cell carcinoma (OSCC) patients generally have a

217 ssible association between bacteria and oral squamous cell carcinoma (OSCC) remain inconclusive, larg

218 The most common form of oral cancer is oral squamous cell carcinoma (OSCC).

219 ors with stage I adenocarcinoma (P<0.003) or squamous cell carcinoma (P=0.023) in the TCGA data set.

220 nic mouse model of breast cancer and in oral squamous cell carcinoma patients, tumor development was

221 was more apparent in adenocarcinoma than in squamous cell carcinoma patients.

222 rofile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum

223 ments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetux

224 Squamous cell carcinoma-related oncogene (SCCRO)/DCUN1D1

225 SCCRO (squamous cell carcinoma-related oncogene; also known as

226 determinants of susceptibility to cutaneous squamous cell carcinoma remain largely unknown.

227 Cutaneous squamous cell carcinoma represents the second most commo

228 Development of cervical squamous cell carcinoma requires increased expression of

229 thway; SNPs at these loci appear to modulate squamous cell carcinoma risk independently of the pigmen

230 from the 1000 Genomes Project and esophageal squamous cell carcinoma samples show that seeksv has hig

231 Malignant tumors included melanoma (12%), squamous cell carcinoma (SCC) (9%), lymphoma (7%), and o

232 uded 53 patients with a history of cutaneous squamous cell carcinoma (SCC) after a first kidney trans

233 ic immunosuppression promotes nonmelanocytic squamous cell carcinoma (SCC) after kidney transplantati

234 ng keratinocyte cancers, including cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (

235 Here we document TCF7L1 upregulation in skin squamous cell carcinoma (SCC) and demonstrate that TCF7L

236 alignant skin lesions that can progress into squamous cell carcinoma (SCC) and invasive SCC if left u

237 It is postulated to increase the risk of squamous cell carcinoma (SCC) and other skin cancers in

238 ends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) are few and appear contrad

239 signaling mediators, but their functions in squamous cell carcinoma (SCC) are unclear.

240 Here we demonstrate for the first time that squamous cell carcinoma (SCC) EVs were enriched with the

241 fferentiating basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) from healthy tissue.

242 bution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipie

243 ing to detect basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in Mohs micrographic surge

244 d incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) in QSkin, a prospective st

245 lta T cells protect against the formation of squamous cell carcinoma (SCC) in several models.

246 Anal squamous cell carcinoma (SCC) is associated with both hu

247 ients (4.4%) had a partial response; one had squamous cell carcinoma (SCC) of the anus and one had SC

248 Patients with squamous cell carcinoma (SCC) of the cervix or vulva hav

249 to urinary arsenic concentration and risk of squamous cell carcinoma (SCC) of the skin in a U.S. popu

250 18)F-FDG phosphorylation rate were higher in squamous cell carcinoma (SCC) than in adenocarcinoma (AC

251 Here, we report in a murine model of skin squamous cell carcinoma (SCC) that nuclear FAK regulates

252 ching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (

253 The age-standardized incidence rate of squamous cell carcinoma (SCC) was highest among black pe

254 ophagus (BE), columnar cell metaplasia (CM), squamous cell carcinoma (SCC), and squamous epithelium (

255 s), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common cance

256 s), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common cance

257 rs for posttransplant skin cancer, including squamous cell carcinoma (SCC), melanoma (MM), and Merkel

258 Lung squamous cell carcinoma (SCC), strongly associated with

259 of tumor-infiltrating T lymphocytes (TIL) in squamous cell carcinoma (SCC), using a systems biologic

260 n lung adenocarcinoma (LUAD) but not in lung squamous cell carcinoma (SCC).

261 ), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

262 r outcomes in many human tumor types such as squamous cell carcinoma (SCC).

263 s) are found in many cancer types, including squamous cell carcinoma (SCC).

264 A)-induced hamster cheek pouch model of oral squamous cell carcinoma (SCC).

265 The associations were somewhat stronger in squamous cell carcinomas (SCC, OR = 4.90) than in urothe

266 Keratinocyte carcinomas (KCs), consisting of squamous cell carcinomas (SCCs) and basal cell carcinoma

267 Squamous cell carcinomas (SCCs) are heterogeneous tumors

268 multiple human papillomavirus (HPV)-positive squamous cell carcinomas (SCCs) arise.

269 Squamous cell carcinomas (SCCs) derived from interfollic

270 gs cooperate to act as a tumor suppressor in squamous cell carcinomas (SCCs).

271 with FGFR1 amplification found in 10-20% of squamous cell carcinomas (SCCs).

272 lanomas, 4 hemangiomas, 4 dermatofibromas, 2 squamous cell carcinomas [SCCs]) was selected and shown

273 abilized DeltaNp63alpha to enhance epidermal squamous cell carcinoma spheroid formation, invasion, an

274 Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two predominant s

275 denocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified u

276 illary urothelial carcinoma, small cell, and squamous cell carcinoma subtypes of invasive bladder can

277 surgical treatment modalities for subungual squamous cell carcinoma (SUSCC) without bone invasion ne

278 However, the mechanisms underlying squamous cell carcinoma susceptibility are unclear.

279 hat SNP309G allele actually protects against squamous cell carcinoma susceptibility.

280 letion alleles is 50% in 143 genotyped oral squamous cell carcinoma -Taiwan samples (27A3B (-/-):89A

281 was associated with a nonlinear reduction in squamous cell carcinoma that became attenuated as consum

282 tion germline polymorphism in Taiwanese oral squamous cell carcinoma that impacts expression of APOBE

283 epidermal cancer stem cells (ECS cells), in squamous cell carcinoma, that form rapidly growing, inva

284 of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1.

285 e establishes a chromatin state predisposing squamous cell carcinomas to undergo EMT and metastasis,

286 In mice bearing esophageal squamous cell carcinoma tumors, to estimate uptake (K),

287 Methods Adult patients with oral cavity squamous cell carcinoma undergoing upfront surgical rese

288 with subgroup analyses by histological type (squamous cell carcinoma vs adenocarcinoma) and type of n

289 chanism leading to the development of vulvar squamous cell carcinoma (VSCC) from vulvar lichen sclero

290 sophageal adenocarcinoma, but not esophageal squamous cell carcinoma, was associated with reduced eso

291 prised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, in

292 man papilloma virus-associated oropharyngeal squamous cell carcinoma, we hypothesized that adding cet

293 and in the prestyloid parapharyngeal space, squamous cell carcinoma were the most common lesions, re

294 r tumors specimens (319 adenocarcinomas; 142 squamous cell carcinomas) were profiled from 245 black p

295 e aspiration from the mass was suggestive of squamous cell carcinoma, which was confirmed on immunohi

296 al sources are lacking, such as in basal and squamous cell carcinomas, which are not included in nati

297 t in non-Hispanic whites, whereas esophageal squamous cell carcinoma with risk factors of tobacco and

298 Using 313 adenocarcinomas and 138 squamous cell carcinomas with genetically supported ance

299 patients with non-squamous cell carcinoma or squamous cell carcinoma (without positive markers, eg, E

300 dependence on the required imaging label in squamous cell carcinoma xenografts.